Literature DB >> 13924838

Clinical and histopathologic evaluation of the effect of 17-alpha-hydroxyprogesterone-17-n-caproate on endometral carcinoma.

A VARGA, E HENRIKSEN.   

Abstract

Entities:  

Keywords:  ADENOCARCINOMA, PAPILLARY/therapy; ADENOCARCINOMA/therapy; PROGESTERONE/related compounds; UTERUS NEOPLASMS/therapy

Mesh:

Substances:

Year:  1961        PMID: 13924838

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


× No keyword cloud information.
  6 in total

1.  Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.

Authors:  Barbara J Attardi; Anthony Zeleznik; Hyagriv Simhan; Jye Ping Chiao; Donald R Mattison; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

2.  Experimental approaches to endometrial and ovarian cancer.

Authors:  M G Brush
Journal:  Postgrad Med J       Date:  1973-02       Impact factor: 2.401

3.  Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; William E Brady; William Todd; Kimberly Leslie; Edgar G Fischer; Neil S Horowitz; Robert S Mannel; Joan L Walker; Marina Ivanovic; Linda R Duska
Journal:  Int J Gynecol Pathol       Date:  2014-11       Impact factor: 2.762

4.  [In vitro metabolism studies of carcinoma corpus uteri].

Authors:  H Hackl
Journal:  Arch Gynakol       Date:  1966

Review 5.  Current status of the management of patients with endocrine-sensitive tumors. II. Carcinoma of the prostate, endometrium, thyroid, kidney and miscellaneous tumors.

Authors:  L G Crowley; S A Duwe
Journal:  Calif Med       Date:  1969-02

Review 6.  Conservative management of patients with early endometrial carcinoma: a systematic review.

Authors:  Luis Chiva de Agustín; Fernando Lapuente Sastre; Virginia Corraliza Galán; Luis Granados Galainena; Antonio González Martín; Lucía González Cortijo; Natalia Carballo González
Journal:  Clin Transl Oncol       Date:  2008-03       Impact factor: 3.405

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.